41 Highlights Inflammatory bowel disease (IBD) features aberrant immune responses against antigens that are usually not recognized by the host immune system, but the exact pathogenic role of these responses and potential implications for patients remain unknown. The utility of well-established serological antibodies in IBD, e.g. anti-S. cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), remains poor. Novel high-throughput methods such as protein arrays, PhIP-Seq and BCRseq have deepened our understanding of the changes in the antibody repertoire in patients with IBD compared to healthy individuals. Leveraging these innovative techniques to profile large prospective longitudinal cohorts could both improve our understanding of IBD immunopathogenesis and reveal novel targets for disease diagnostics, therapeutic interventions and opportunities for prevention. Antibody signatures in IBD: developments and applications
RkJQdWJsaXNoZXIy MjY0ODMw